Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 31 July 2025 AM
The PBAC has dropped the agenda for its November meeting with 29 new listing requests and two new vaccines for the NIP - as 24 companies jostle for a recommendation.
Celltrion Healthcare has claimed first place with the highest number of new listing requests. The company is seeking recommendations for three biosimilars which could disrupt markets worth a combined $855 million on the PBS.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.